In a 67-year-old man with diabetes mellitus, currently on glipizide 5 mg daily, HbA1c 10.3% uncontrolled for years, and who stopped metformin 1000 mg twice daily, what is the recommended next therapeutic step?

Restart Metformin and Intensify Therapy Immediately

This patient requires immediate reinitiation of metformin (assuming no contraindications) combined with addition of a cardioprotective agent, given his severely uncontrolled diabetes (A1C 10.3%) and age-related cardiovascular risk. The glipizide monotherapy is clearly inadequate and should be reassessed for dose reduction or discontinuation once more effective therapy is established.

Step 1: Restart Metformin as Foundation Therapy

Metformin remains the cornerstone of type 2 diabetes management unless contraindicated 1. The 2025 ADA Standards explicitly state metformin is "effective and safe, is inexpensive and widely available, and reduces risks of microvascular complications, cardiovascular events, and death" 1.

Before restarting metformin:

• Check eGFR (metformin contraindicated if eGFR <30 mL/min/1.73 m²; not recommended to initiate if eGFR 30-45) 2
• Assess for hepatic disease (avoid if present due to lactic acidosis risk) 2
• Screen for excessive alcohol use 2

Dosing strategy:

• Resume at 500 mg daily with dinner (extended-release formulation preferred for tolerability)
• Titrate by 500 mg weekly to target 1000 mg twice daily or 2000 mg extended-release once daily 1
• This gradual approach minimizes GI side effects that likely contributed to initial discontinuation

Step 2: Add Cardioprotective Agent Based on Risk Stratification

At age 67, this patient qualifies as "high cardiovascular risk" per ESC criteria (age ≥50 is a major risk factor) 3. The 2025 ADA guidelines are unequivocal: when A1C is ≥1.5% above goal (this patient is ~2.3% above a reasonable 8% target for his age), dual combination therapy or more potent agents are required 1.

Preferred addition: SGLT2 inhibitor OR GLP-1 RA

The choice depends on specific comorbidities:

Choose SGLT2 Inhibitor if:

• Any evidence of heart failure symptoms or reduced ejection fraction
• eGFR 30-60 mL/min/1.73 m² or albuminuria present
• Patient prefers oral medication
• Caveat: Assess foot care carefully; avoid if active foot ulcers or high amputation risk 3

Choose GLP-1 RA if:

• Weight loss is priority (likely given diabetes duration and poor control)
• No contraindications to injectable therapy
• Patient willing to use injectable medication
• Advantage: Superior A1C reduction when combined with metformin (WMD -1.50%) 4

Both classes provide cardiovascular protection independent of glucose lowering 3. The 2019 ESC guidelines (incorporated into 2021 consensus) give Class IA recommendation for SGLT2 inhibitors or GLP-1 RAs in patients at high CV risk 3.

Step 3: Address the Glipizide

Reduce glipizide dose by 50% or discontinue entirely once new therapy is initiated 1. The 2025 ADA explicitly states: "When initiating a new glucose-lowering medication, reassess the need for and/or dose of medications with higher hypoglycemia risk (i.e., sulfonylureas)" 1.

Rationale:

• Glipizide carries significant hypoglycemia risk, especially in elderly patients 5
• Recent 2026 data confirms short-acting sulfonylureas like glipizide are preferred over long-acting agents in patients ≥64 years, but combination therapy is superior 6
• Sulfonylureas should be used cautiously in older adults 7

Step 4: Consider Basal Insulin if Symptomatic

If this patient has symptoms of hyperglycemia (polyuria, polydipsia, weight loss, blurred vision), initiate basal insulin immediately regardless of other therapy 1. The 2025 ADA states insulin should be considered "if symptoms of hyperglycemia are present or when A1C or blood glucose levels are very high (i.e., A1C >10%)" 1.

If insulin is needed:

• Start basal analog (glargine or detemir) 10 units at bedtime OR 0.1-0.2 units/kg 1
• Titrate by 2 units every 3 days targeting fasting glucose 80-130 mg/dL 1
• Can combine with metformin and GLP-1 RA/SGLT2i 1
• Prescribe glucagon for emergency hypoglycemia 1

Critical Monitoring Points

Reassess in 3 months (not 6 months given severity):

• A1C should decrease by at least 1-1.5%
• If still >1.5% above goal, add third agent or intensify to insulin 1
• Check vitamin B12 annually on metformin (risk of deficiency) 1, 2
• Monitor eGFR at least annually, more frequently given age 2

Common Pitfalls to Avoid

1. Therapeutic inertia: Don't wait another 3-6 months on inadequate therapy. A1C of 10.3% demands immediate intensification 1
2. Continuing sulfonylurea at full dose: This increases hypoglycemia risk when adding more effective agents 1
3. Ignoring why metformin was stopped: Address GI side effects with extended-release formulation and gradual titration 1
4. Overlooking cardiovascular risk: Age 67 automatically qualifies for cardioprotective therapy 3
5. Missing contraindications: Always check renal function before metformin and assess foot health before SGLT2 inhibitors 3, 2